NCT05806671View on ClinicalTrials.gov

Dalpiciclib Plus Fulvestrant With Pyrotinib in Hormone Receptor-positive, HER2-low Advanced Breast Cancer That Progressed on Previous CDK4/6i Plus AI Therapy

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 31, 2023

Primary Completion Date

January 31, 2025

Study Completion Date

December 31, 2025

Conditions

Breast Cancer

Interventions

DRUG

Dalpiciclib

Dalpiciclib 125 mg/day orally continuously dosed for 3 weeks followed by 1 week off

DRUG

Pyrotinib

Pyrotinib 320mg/day orally continuously

DRUG

Fulvestrant

Fulvestrant 500mg intramuscularly on Days 1 and 15 of Cycle 1, and then on Day 1 of each subsequent 28 day cycle

Trial Locations (1)

Unknown

Tianjin Cancer Hospital, Tianjin

All Listed Sponsors

lead

Tianjin Medical University Cancer Institute and Hospital

OTHER

NCT05806671 - Dalpiciclib Plus Fulvestrant With Pyrotinib in Hormone Receptor-positive, HER2-low Advanced Breast Cancer That Progressed on Previous CDK4/6i Plus AI Therapy | Biotech Hunter | Biotech Hunter